Moneycontrol PRO

Outskill Genai

you are here: HomeNewsBusinessStocksRanbaxy may suffer loss of $250 mn on approval woes: Expert

SHOW NAMES

Trending Topics

business

Ranbaxy may suffer loss of $250 mn on approval woes: Expert

Surajit Pal, pharma analyst, Prabhudas Lilladher, expects Teva, Mylan, Sandoz and Dr Reddy‘s Laboratories to benefit from this loss.

first published: Nov 7, 2014 09:41 am

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Live: Will Nifty continue its rangebound move this week? | Opening Bell
The Lawyer Renting in a 120-year-old building in South Mumbai | The Tenant
Nifty On Track To End Week Above 25,500 As Bank & Metal Stocks Lead Rebound| Closing Bell Live
Can Nifty Stage A Friday Fightback After Hitting 3-Week Low? Pine Labs IPO Opens | Opening Bell Live

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347